论文部分内容阅读
非典型抗精神病药物治疗精神分裂症常出现体重增加或脂质代谢紊乱等药物不良反应,且个体差异明显,但机制尚不明确。药物基因组学研究表明,基因多态性可能起着重要的作用。药物可能作用于中枢相关受体,促进摄食,或直接作用于外周的脂肪细胞或肝细胞影响脂质代谢。本文从这两方面综述了与非典型抗精神病药物导致脂代谢不良反应关联较强的基因多态性,为抗精神病药物临床个体化用药提供参考依据。
Atypical antipsychotic treatment of schizophrenia often appear weight gain or lipid metabolism disorders and other adverse drug reactions, and the individual differences significantly, but the mechanism is not yet clear. Pharmacogenomics studies show that genetic polymorphisms may play an important role. Drugs may act on central related receptors, promote feeding, or directly affect the peripheral fat cells or liver cells affect lipid metabolism. This review summarizes the genetic polymorphisms associated with atypical antipsychotics that lead to adverse effects of lipid metabolism from these two aspects and provides a reference for the individualized use of antipsychotics.